The aim of this study was to determine the role of the tumor
necrosis factor like weak inducer of apoptosis (TWEAK) as
a serum biomarker of neuropsychiatric involvement in systemic
lupus erythematosus (NPSLE). Levels of TWEAK levels were
measured in sera of 92 patients with systemic lupus
erythematosus (SLE), including 28 patients with neuropsychiatric
lupus, and in 59 healthy controls using ELISA. All SLE patients
underwent rheumatological, neurological and psychiatric
assessments. We found no significant differences in TWEAK
levels, between SLE patients and the healthy controls
(p=0.2411). Similarly, no difference was observed between the
subgroup of NPSLE and healthy controls (p=0.7658). The mean
SLE disease activity (SLEDAI) was 13.25. No correlations
between TWEAK levels with disease activity (SLEDAI, r=0.2113,
p= 0.2805) or the most common NPSLE manifestations such as
headache (r=0.2079), seizures (r=0.1101), cerebrovascular
disease (r=- 0.2347), cognitive dysfunction (r=0.1597) and
anxiety (r=0.1397) were observed. Our data do not support the
use of serum TWEAK as a discriminating biomarker for NPSLE.
The role of the TWEAK in NPSLE remains to be investigated.